Issue: June 2011
June 01, 2011
1 min read
Save

FDA approves fidaxomicin for C. difficile infection

Issue: June 2011
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA has approved fidaxomicin twice-daily tablets for the treatment of Clostridium difficile-associated diarrhea in adults.

FDA approval was based upon the safety and efficacy of fidaxomicin (Dificid, Optimer Pharmaceuticals) in two trials consisting of 564 patients with C. difficile infection that compared fidaxomicin with vancomycin.

“In recent years, many in the infectious disease community have seen an increase in the number of cases of people with a C. difficile infection,” Edward Cox, MD, MPH, director of the FDA’s Office of Antimicrobial Products at the Center for Drug Evaluation and Research, said in a press release. “[Fidaxomicin] is an effective new treatment option for patients who develop C. difficile-associated diarrhea.”

Common adverse events included nausea, vomiting, headache, abdominal pain and diarrhea.

Twitter Follow InfectiousDiseaseNews.com on Twitter.